Long-Lasting Hemophilia Treatment Succeeds in Phase III

Partners Biogen Idec and Swedish Orphan Biovitrum reported positive data from a Phase III study evaluating the long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.
Genetic Engineering & Biotechnology News